10-K: Tivic Health Systems Reports 2024 Results, Outlines Strategic Focus on Bioelectronic and Biopharmaceutical Programs

Tivic Health Systems' 2024 10-K filing details a year of strategic shifts, including a focus on bioelectronic medicine and the acquisition of a late-stage biopharmaceutical asset, alongside financial challenges and efforts to ensure future growth.

Summary

• Tivic Health Systems reported a net loss of $5.7 million for the year ended December 31, 2024, compared to a net loss of $8.2 million in 2023.
• Revenue decreased by 34% to $0.8 million in 2024 from $1.2 million in 2023, primarily due to decreased unit sales of the ClearUP device.
• The company is focusing on bioelectronic medicine, particularly non-invasive vagus nerve stimulation (ncVNS), and has acquired a late-stage biopharmaceutical asset, Entolimod, for treating acute radiation syndrome (ARS).
• Tivic Health is facing financial challenges, with concerns about its ability to continue as a going concern due to recurring losses and negative cash flows.
• The company is seeking additional capital through equity or debt offerings to fund its operations and strategic plans.
• A material weakness in internal control over financial reporting was identified, which could impact the accuracy of financial statements.
• The company is working to develop and commercialize its ncVNS technology, with clinical research underway to optimize device parameters.
• Tivic Health is also expanding its intellectual property portfolio and exploring opportunities for inorganic growth through licensing and acquisitions.
• The company is subject to various regulations, including those related to medical devices, biopharmaceuticals, data privacy, and cybersecurity.
• A reverse stock split was implemented in March 2025 to regain compliance with Nasdaq listing requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the acquisition of Entolimod and promising clinical research, the financial challenges and going concern uncertainty weigh heavily on the overall sentiment.

Positives

• Net losses decreased year-over-year, indicating improved cost management.
• The acquisition of Entolimod provides a potential new revenue stream and diversifies the company's product portfolio.
• Clinical research on ncVNS shows promising results, suggesting potential for future product development.
• The company is actively working to address the material weakness in internal control over financial reporting.
• The Equity Purchase Agreement with Mast Hill Fund provides access to additional capital.
• The company is expanding its intellectual property portfolio with new patents.
• The company is working with Fletcher Spaght to develop a commercial strategy for ncVNS.

Negatives

• Revenue decreased by 34% year-over-year, indicating challenges in sales and marketing.
• The company has a history of net losses and may not achieve or maintain profitability in the future.
• There is substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified.
• The company is reliant on raising additional capital to fund its operations.
• The company has limited experience in the biopharmaceutical sector.

Risks

• The company's cash and financial resources may be insufficient to meet its anticipated needs for the next twelve months.
• The company's operating results may be volatile and may not be a reliable indicator of future performance.
• The company may not be able to effectively integrate licensed or acquired technology into its operations.
• Disruptions at the FDA and foreign regulatory authorities could negatively impact the company's business.
• Economic uncertainty and capital markets disruption could harm the company's financial condition and results of operations.
• Changes in United States and China relations, as well as relations with other countries, and/or regulations may adversely impact the company's business.
• The company relies on third parties to supply and manufacture its devices.
• The company is highly dependent on its intellectual property (IP) and its methods of protecting its IP may not be adequate or could be costly.
• The company's stock price has fluctuated significantly since its initial public offering (IPO), and may continue to fluctuate significantly.
• If the company is unable to comply with the continued listing requirements of the Nasdaq Capital Market, its common stock could be delisted.

Future Outlook

The company expects to incur substantial additional operating losses for the foreseeable future to expand its markets, complete development of new products, obtain regulatory approvals, launch and commercialize its products, and continue research and development programs. The company plans to increase its research and development investments in its vagus nerve platform and clinical applications thereof in 2025. The company also plans to advance the development of its licensed TLR5 agonist programs, known as Entolimod and Entolasta.

Management Comments

• The magnitude of our ncVNS data imply potential for greater clinical effects and enhanced reproducibility than demonstrated by previous studies of non-invasive VNS devices.
• These results in healthy subjects suggest our ncVNS approach may have clinical utility in several patient populations, including those with post-traumatic stress disorder, cardiac disease, inflammatory conditions, and ischemic stroke, among others.

Industry Context

The company operates in the emerging bioelectronic medicine market, which is focused on treating diseases by modulating electrical signals in nerve pathways. The company also operates in the over-the-counter allergy, cough, cold and flu treatments market. The company faces competition from established pharmaceutical companies and other bioelectronic device developers.

Comparison to Industry Standards

• The VNS market is forecasted by Polaris Research to reach $21 billion in the next five years, growing at a compounded annual growth rate of 10.6%.
• The over-the-counter allergy, cough, cold and flu treatments market was projected by Mintel Group Ltd. to be an $11.1 billion market by 2025 in the U.S. alone.
• The ARS market is estimated by CoherentMI to be valued at approximately $5.2 billion in 2024, and further estimates that it will reach $7.3 billion by 2031.
• The company's ncVNS intervention resulted in a 97% increase in the root mean square of successive differences (RMSSD) measure of heart rate variability, which is a widely accepted proxy for vagus nerve activity.
• The company's ncVNS intervention increased frontal theta power by 24% and reduced gamma power in several brain regions, including a 66% reduction in frontal gamma power these changes in brain activity are consistent with reduced arousal and anxiety.
• During ncVNS stimulation, subjects had sustained pupil constriction, a 9.5% reduction in pupil diameter, an outcome associated with engagement of the vagus nerve and activation of the parasympathetic nervous system.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not currently a party to any material legal proceedings.

Related Party Transactions

• In December 2021, the Company entered into an agreement with a significant shareholder for certain product development consultation services. During the years ended December 31, 2024 and 2023, the Company incurred $5 thousand and $14 thousand, respectively, of expenses in connection with the agreement.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by cost-cutting measures and potential restructuring.
• Customers may benefit from new product development and expanded indications.
• Suppliers may be impacted by changes in manufacturing and distribution strategies.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• Continue development and commercialization of ncVNS technology.
• Advance the development of Entolimod and Entolasta.
• Seek regulatory approval for new products and indications.
• Secure additional funding through equity or debt offerings.
• Address the material weakness in internal control over financial reporting.

Key Dates

Keywords

Tivic Health, bioelectronic medicine, biopharmaceutical, ClearUP, vagus nerve stimulation, Entolimod, acute radiation syndrome, financial results, risk factors, regulatory approval